Andere Kunden interessierten sich auch für
![Dementia Confidential : Viser le vieillissement normal plutôt que la démence]( "Dementia Confidential : Viser le vieillissement normal plutôt que la démence")
Dementia Confidential : Viser le vieillissement normal plutôt que la démence26,99 €![Demenz vertraulich: Normales Altern statt Demenz anstreben]( "Demenz vertraulich: Normales Altern statt Demenz anstreben")
Demenz vertraulich: Normales Altern statt Demenz anstreben39,90 €![Bursting Neurons and Fading Memories]( "Bursting Neurons and Fading Memories")
Bursting Neurons and Fading Memories74,99 €![A guide to understanding Alzheimer's disease]( "A guide to understanding Alzheimer's disease")
A guide to understanding Alzheimer's disease18,99 €![Understanding Alzheimer's: A Journey Through Causes, Symptoms, and Research]( "Understanding Alzheimer's: A Journey Through Causes, Symptoms, and Research")
Understanding Alzheimer's: A Journey Through Causes, Symptoms, and Research28,29 €![Biometals in Autism Spectrum Disorders]( "Biometals in Autism Spectrum Disorders")
Biometals in Autism Spectrum Disorders162,99 €![Disease-Modifying Targets in Neurodegenerative Disorders]( "Disease-Modifying Targets in Neurodegenerative Disorders")
Disease-Modifying Targets in Neurodegenerative Disorders79,99 €
A frequent coexistence of cerebrovascular pathology and Alzheimer's disease pathology has been observed over past decades. Accordingly, there is much documentary evidence indicating that microvascular endothelial dysfunction, due to cerebrovascular risk factors (e.g., atherosclerosis, obesity, diabetes, smoking, hypertension, aging), precedes cognitive decline in Alzheimer's disease and contributes to its pathogenesis. This book describes a multitasking combination therapeutic (i.e., biomimetic lipid nanocarrier for several drugs) which crosses the blood-brain barrier, and readily binds to populations of cell-surface scavenger receptors (mainly SR-BI) simultaneously in brain tissue. These same receptor classes have been extensively reported to occur prominently on various Alzheimer's-related cell types. Hence, this multitasking (targeted drug-delivery) therapeutic may also display greater effectiveness at different stages of Alzheimer's disease. Such a multitasking therapeutic approach could be especially useful to pharmaceutical researchers, graduate students and medical professionals by representing a promising way to treat, delay, or even prevent the disease in the future.